European network for the case-population surveillance of rare diseases (Euronet). A prospective feasibility study

European Journal of Clinical Pharmacology

Volumn 53, Issue 5, 1998, Pages 299-302

  Capella D ^a   Laporte, J R ^a   Vidal, X ^a   Wiholm, B E ^b   Begaud B ^c   Langman, M J S ^d   Rawlins, M ^e  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

^c HÔPITAL PELLEGRIN   (France)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

European network; Surveillance of rare disease

Indexed keywords

ARTICLE; COMPUTER NETWORK; DISEASE ASSOCIATION; DRUG SURVEILLANCE PROGRAM; DRUG USE; EUROPE; NONHUMAN; PRIORITY JOURNAL; SCREENING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGRANULOCYTOSIS; DRUG UTILIZATION; EPIDERMAL NECROLYSIS, TOXIC; EUROPE; FEASIBILITY STUDIES; HUMANS; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; STEVENS-JOHNSON SYNDROME;

EID: 0031938484     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050382     Document Type: Article

References (5)

1. Spriet-Pourra C, Auriche M (1994) Drug withdrawal from the market for safety in three European countries: contributing reasons and implications. In: GN Fracchia (ed) European medicines research. IOS Press, pp 267-275
2. Kaufman DW, Kelly JP, Levy M, Shapiro S (1991) The drug etiology of agranulocytosis and aplastic anemia. Oxford University Press, New York
3. Kelly JP, Auquier A, Rzany B, Naldi L, Bastuji-Garin S, Correia O, Shapiro S, Kaufman DW (1995) An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods. J Clin Epidemiol 48: 1099-1108
4. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau J-C (1993) Clinical classification of cases of toxic epidermal necrolysis. Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129: 92-96
5. Roujeau J-C (1994) The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 102: 28S-30S